Table 4.

Compounds that target α9-containing nAChRs, mechanism of action, and therapeutic effects in models of pain and inflammation

Compound	Mechanism of Action	Pain or inflammation model	Therapeutic effects	Ref.
RgIA	antagonist	CCI	Reduced mechanical allodynia and mechanical hyperalgesia, infiltration of immune cells	[145]
		Oxaliplatin-induced neuropathy	Reduced mechanical hyperalgesia, cold allodynia; disease modifying effects	[141]
RgIA4	antagonist	Oxaliplatin-induced neuropathy	Reduced mechanical hyperalgesia and cold allodynia; disease modifying effects	[143]
Vc1.1	antagonist	CCI	Reduced mechanical allodynia, mechanical hyperalgesia, infiltration of immune cells; disease modifying effects	[145, 147]
GeXIVA	antagonist	CCI	Reduced mechanical hyperalgesia	[161, 186]
ZZ-204G	antagonist	CCI	Reduced mechanical hyperalgesia	[167]
		Formalin test	Reduced inflammatory pain	[167]
ZZ1-61c	antagonist	Vincristine-induced neuropathy	Reduced mechanical allodynia and mechanical hyperalgesia	[168]